Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 133 clinical trials
PRO-MERIT (Prostate Cancer Messenger RNA Immunotherapy)

Open-label, multicenter, dose titration and expansion three-arm trial to evaluate the safety, tolerability, immunogenicity, and preliminary efficacy of W_pro1 cancer vaccine (W_pro1) in patients with metastatic castration resistant prostate cancer (mCRPC) W_pro1 in combination with goserelin acetate with or without cemiplimab, in patients with high-risk, localized prostate cancer (LPC)

cancer vaccine
major surgery
saw palmetto
squamous cell carcinoma of the skin
luteinizing hormone
  • 2 views
  • 19 Feb, 2024
  • 16 locations
Interactive Decision Aid for Men Diagnosed With Prostate Cancer

Prostate cancer is the second leading cause of cancer related deaths in the western world (National Cancer Institute, 2011). Prostate cancer diagnosis relates to significant psychological distress (Roesch et al, 2005; Hervouet et al, 2005).

cancer diagnosis
  • 0 views
  • 19 Feb, 2024
  • 1 location
Molecular Imaging of Prostate Cancer Using Radiofluorinated PSMA Ligand

Eligible patients have prostate cancer that was treated with surgery or radiation therapy for localized disease and there is evidence of biochemical recurrence and/or metastases on conventional imaging.The objective of this study is to assess the performance in detection of prostate cancer of a new positron emission tomography (PET) radiotracer …

fluciclovine (18f)
metastasis
pet/mri
localized disease
MRI
  • 0 views
  • 19 Feb, 2024
  • 1 location
EMPOWER Men to Reduce Weight and Inhibit Prostate Cancer Progression

This study will evaluate whether a lifestyle intervention focused on weight loss, EMPOWER, reduces prostate cancer progression at 12 months among men with biochemical recurrence following local treatment for prostate cancer. Half of the men will be randomized to receive the EMPOWER intervention, while the other half will receive standard …

adenocarcinoma of prostate
testosterone level
metastasis
prostate cancer
body mass index
  • 0 views
  • 19 Feb, 2024
  • 1 location
18F-PSMA-1007 PET Imaging to Detect Primary Prostate Cancer

To study the added value of 18F-PSMA-1007 PET to mpMRI in the detection of local prostate cancer lesions.

pet/ct scan
positron emission tomography
digital rectal examination
multiparametric magnetic resonance imaging
  • 0 views
  • 19 Feb, 2024
  • 1 location
Postop Hypofractionated Radiation Therapy and LHRH in Patients With Prostate Cancer

Prostate cancer is the second most common cancer among Canadian men of which approximately 20-30% present with high-risk tumour characteristic.

immunological adjuvant
adenocarcinoma of prostate
digital rectal examination
metastasis
bone metastases
  • 0 views
  • 19 Feb, 2024
  • 2 locations
Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer

This is a Phase 1b/2, open-label, multicenter platform trial to evaluate the antitumor activity and safety of AB928-based combination therapy in participants with metastatic castrate resistant prostate cancer (mCRPC).

measurable disease
combined modality therapy
enzalutamide
testosterone
prostate cancer
  • 0 views
  • 19 Feb, 2024
  • 22 locations
Oral EPI-7386 in Patients With Metastatic Castration-Resistant Prostate Cancer

This is a phase I, clinical research study of EPI-7386, an investigational drug being studied as a treatment for patients with prostate cancer. All patients in the study will receive EPI-7386. Since this is the first study of EPI-7386 in humans, there is no information about how it affects people …

metastasis
metastatic castration-resistant prostate cancer
diphosphonates
progressive disease
bone lesion
  • 0 views
  • 19 Feb, 2024
  • 5 locations
Study of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer

Evaluate the safety and tolerability of AMG 509 in adult subjects and determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D).

platelet transfusion
metastasis
abiraterone
gonadotropin releasing hormone
antiandrogen therapy
  • 0 views
  • 19 Feb, 2024
  • 4 locations
Early Prostate Cancer Recurrence With PSMA PET Positive Unilateral Pelvic Lesion(s)

This increasingly allows individualized specific therapy of patients with prostate cancer recurrence. PSMA PET has now been included in national and international guidelines for the diagnosis of patients with biochemical recurrence of prostate cancer.

cancer recurrence
metastasis
local therapy
prostatectomy
molecular imaging
  • 0 views
  • 19 Feb, 2024
  • 1 location